COSTA MESA, Calif.--(BUSINESS WIRE)--July 12, 2006--Synthetic Blood International, Inc. (OTCBB:SYBD - News) today announced treatment of the fifth and sixth patients in its eight-patient Phase II proof-of-concept Oxycyte(TM) study in traumatic brain injury. Oxycyte administration significantly increased brain oxygen tension over baseline in these patients, which is consistent with the results in the first four patients.
